Detalhe da pesquisa
1.
Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
BMC Endocr Disord
; 19(1): 132, 2019 Dec 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31796048
2.
Ðn affordability of statins therapy - comparative analysis between Ukraine and Bulgaria.
BMC Health Serv Res
; 19(1): 902, 2019 Nov 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31775736
3.
The role of insurance policies in the drug pricing landscape.
Expert Rev Pharmacoecon Outcomes Res
; 24(2): 189-202, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38064353
4.
Tackling reimbursement challenges to fair access to medicines - introduction to the topic.
Expert Rev Pharmacoecon Outcomes Res
; 23(6): 597-606, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37055731
5.
Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment.
Front Public Health
; 11: 1088121, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37181704
6.
Recommendations for patient involvement in health technology assessment in Central and Eastern European countries.
Front Public Health
; 11: 1176200, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37465169
7.
Comparison of Cardiovascular Medicines Prices in Four European Countries.
Front Public Health
; 8: 433, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32974262
8.
Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe.
Orphanet J Rare Dis
; 15(1): 277, 2020 10 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33032634
9.
Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria.
PLoS One
; 15(5): e0232815, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32392235
10.
Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
Expert Rev Pharmacoecon Outcomes Res
; 19(6): 733-742, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30900482
11.
Incretins and SGLT-2i Therapy of Type 2 Diabetes - Real Life Study of Their Therapeutic and Economic Effects.
Front Pharmacol
; 10: 364, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31040779
12.
Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries.
Front Pharmacol
; 10: 487, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31139080
13.
An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries.
Front Public Health
; 6: 61, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29556491
14.
Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis.
Front Pharmacol
; 9: 1070, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30294275
15.
Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries.
Front Pharmacol
; 9: 795, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30079023
16.
Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review.
Front Pharmacol
; 8: 892, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29326583
17.
Use of complementary and alternative medicine by children in Europe: published data and expert perspectives.
Complement Ther Med
; 21 Suppl 1: S34-47, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23578916